Compare MXC & BCDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MXC | BCDA |
|---|---|---|
| Founded | 1972 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.6M | 14.1M |
| IPO Year | 1995 | 2009 |
| Metric | MXC | BCDA |
|---|---|---|
| Price | $10.32 | $1.11 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $25.00 |
| AVG Volume (30 Days) | 25.3K | ★ 208.4K |
| Earning Date | 02-10-2026 | 05-13-2026 |
| Dividend Yield | ★ 1.02% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.24 | N/A |
| Revenue | ★ $2,705,235.00 | $479,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $41.46 | ★ N/A |
| Revenue Growth | ★ 7.12 | N/A |
| 52 Week Low | $7.16 | $0.75 |
| 52 Week High | $16.48 | $2.29 |
| Indicator | MXC | BCDA |
|---|---|---|
| Relative Strength Index (RSI) | 58.13 | 60.76 |
| Support Level | $9.89 | $1.11 |
| Resistance Level | $10.45 | $1.28 |
| Average True Range (ATR) | 0.65 | 0.07 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 82.32 | 66.36 |
Mexco Energy Corporation is an independent oil and gas company. It is engaged in the acquisition, exploration, development, and production of natural gas and crude oil properties located in the United States. The company carried out its operation in the Permian Basin of West Texas. It is focusing on two primary areas, the Delaware Basin located in the Western portion of the Permian Basin including Lea and Eddy Counties, New Mexico and Loving County, Texas, and the Midland Basin located in the Eastern portion of the Permian Basin including Reagan, Upton, Midland, Martin, Howard, and Glasscock Counties, Texas. The company generates revenue from Oil sales, Natural gas sales, oil and gas royalty interests.
BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an off the shelf cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).